JP6166471B2 - ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法 - Google Patents
ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法 Download PDFInfo
- Publication number
- JP6166471B2 JP6166471B2 JP2016526009A JP2016526009A JP6166471B2 JP 6166471 B2 JP6166471 B2 JP 6166471B2 JP 2016526009 A JP2016526009 A JP 2016526009A JP 2016526009 A JP2016526009 A JP 2016526009A JP 6166471 B2 JP6166471 B2 JP 6166471B2
- Authority
- JP
- Japan
- Prior art keywords
- zoledronic acid
- dosage form
- oral dosage
- mammal
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 title claims description 607
- 229960004276 zoledronic acid Drugs 0.000 title claims description 606
- 239000006186 oral dosage form Substances 0.000 title claims description 305
- 238000000034 method Methods 0.000 title claims description 207
- 241000124008 Mammalia Species 0.000 claims description 216
- 239000002552 dosage form Substances 0.000 claims description 176
- 230000036470 plasma concentration Effects 0.000 claims description 115
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical group [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 110
- 239000007787 solid Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 241000894007 species Species 0.000 description 126
- 208000002193 Pain Diseases 0.000 description 124
- 230000036407 pain Effects 0.000 description 122
- 241000282414 Homo sapiens Species 0.000 description 97
- 230000002459 sustained effect Effects 0.000 description 47
- 229940122361 Bisphosphonate Drugs 0.000 description 44
- 238000011282 treatment Methods 0.000 description 42
- 150000004663 bisphosphonates Chemical class 0.000 description 38
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 36
- 206010028980 Neoplasm Diseases 0.000 description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 33
- 201000010099 disease Diseases 0.000 description 32
- 201000011510 cancer Diseases 0.000 description 31
- 206010065390 Inflammatory pain Diseases 0.000 description 29
- 230000003442 weekly effect Effects 0.000 description 29
- 241001465754 Metazoa Species 0.000 description 27
- 210000000988 bone and bone Anatomy 0.000 description 27
- 230000002917 arthritic effect Effects 0.000 description 24
- 210000000548 hind-foot Anatomy 0.000 description 21
- 239000000825 pharmaceutical preparation Substances 0.000 description 19
- 229940127557 pharmaceutical product Drugs 0.000 description 19
- 241000700159 Rattus Species 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 206010003246 arthritis Diseases 0.000 description 17
- 239000002904 solvent Substances 0.000 description 17
- 239000003814 drug Substances 0.000 description 16
- 239000003826 tablet Substances 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 14
- 150000001875 compounds Chemical class 0.000 description 13
- 238000005259 measurement Methods 0.000 description 13
- -1 Bisphosphonate compounds Chemical class 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 12
- 210000002683 foot Anatomy 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 230000008030 elimination Effects 0.000 description 10
- 238000003379 elimination reaction Methods 0.000 description 10
- 238000011552 rat model Methods 0.000 description 10
- 238000011084 recovery Methods 0.000 description 10
- 208000011580 syndromic disease Diseases 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 201000008482 osteoarthritis Diseases 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 206010017076 Fracture Diseases 0.000 description 8
- 208000001132 Osteoporosis Diseases 0.000 description 8
- OPQQEYHAVUNQNA-UHFFFAOYSA-L disodium;hydroxy-[1-hydroxy-1-[hydroxy(oxido)phosphoryl]-2-imidazol-1-ylethyl]phosphinate Chemical compound [Na+].[Na+].OP(=O)([O-])C(P(O)([O-])=O)(O)CN1C=CN=C1 OPQQEYHAVUNQNA-UHFFFAOYSA-L 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 241000282472 Canis lupus familiaris Species 0.000 description 7
- 239000003623 enhancer Substances 0.000 description 7
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 6
- 208000008035 Back Pain Diseases 0.000 description 6
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 6
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 6
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 description 6
- 229940062527 alendronate Drugs 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229960002286 clodronic acid Drugs 0.000 description 6
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 229950006971 incadronic acid Drugs 0.000 description 6
- LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 description 6
- 230000004968 inflammatory condition Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 6
- 239000008247 solid mixture Substances 0.000 description 6
- 208000010392 Bone Fractures Diseases 0.000 description 5
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 5
- 208000008930 Low Back Pain Diseases 0.000 description 5
- 208000000114 Pain Threshold Diseases 0.000 description 5
- 238000007906 compression Methods 0.000 description 5
- 230000006835 compression Effects 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 210000003141 lower extremity Anatomy 0.000 description 5
- 238000002595 magnetic resonance imaging Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000037040 pain threshold Effects 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 229940089617 risedronate Drugs 0.000 description 5
- 230000001052 transient effect Effects 0.000 description 5
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 4
- 206010058019 Cancer Pain Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 208000004454 Hyperalgesia Diseases 0.000 description 4
- 206010027452 Metastases to bone Diseases 0.000 description 4
- 208000034578 Multiple myelomas Diseases 0.000 description 4
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 201000002661 Spondylitis Diseases 0.000 description 4
- 238000010306 acid treatment Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000002059 diagnostic imaging Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 229960005236 ibandronic acid Drugs 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 229950004969 olpadronic acid Drugs 0.000 description 4
- 229960003978 pamidronic acid Drugs 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229960005324 tiludronic acid Drugs 0.000 description 4
- 208000007815 Acquired Hyperostosis Syndrome Diseases 0.000 description 3
- 208000025705 Axial Spondyloarthritis Diseases 0.000 description 3
- 206010051763 Bone marrow oedema Diseases 0.000 description 3
- 208000001387 Causalgia Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000012659 Joint disease Diseases 0.000 description 3
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 208000010191 Osteitis Deformans Diseases 0.000 description 3
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 3
- 201000004854 SAPHO syndrome Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 210000001872 metatarsal bone Anatomy 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 208000021722 neuropathic pain Diseases 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 159000000000 sodium salts Chemical group 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 2
- 208000036487 Arthropathies Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 208000037147 Hypercalcaemia Diseases 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 2
- 229920003354 Modic® Polymers 0.000 description 2
- 206010031252 Osteomyelitis Diseases 0.000 description 2
- 208000027067 Paget disease of bone Diseases 0.000 description 2
- 208000014677 Periarticular disease Diseases 0.000 description 2
- 206010037779 Radiculopathy Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 208000016738 bone Paget disease Diseases 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000006189 buccal tablet Substances 0.000 description 2
- 239000007958 cherry flavor Substances 0.000 description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 201000010103 fibrous dysplasia Diseases 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 229910021485 fumed silica Inorganic materials 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 230000000148 hypercalcaemia Effects 0.000 description 2
- 208000030915 hypercalcemia disease Diseases 0.000 description 2
- 229940015872 ibandronate Drugs 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 229940046231 pamidronate Drugs 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229940019375 tiludronate Drugs 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000008822 Ankylosis Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000025962 Crush injury Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 201000008370 Discitis Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000002966 Giant Cell Tumor of Bone Diseases 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010060738 Intervertebral discitis Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000031264 Nerve root compression Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000005268 Neurogenic Arthropathy Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010029326 Neuropathic arthropathy Diseases 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 206010031009 Oral pain Diseases 0.000 description 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 206010058571 Spinal cord infarction Diseases 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 208000004367 Tibial Fractures Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 201000011143 bone giant cell tumor Diseases 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- IEJZOPBVBXAOBH-UHFFFAOYSA-L disodium;(1-hydroxy-2-imidazol-1-yl-1-phosphonatoethyl)phosphonic acid;tetrahydrate Chemical compound O.O.O.O.[Na+].[Na+].OP(=O)([O-])C(P(O)([O-])=O)(O)CN1C=CN=C1 IEJZOPBVBXAOBH-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 108010084652 homeobox protein PITX1 Proteins 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 206010033103 otosclerosis Diseases 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 229960000759 risedronic acid Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 206010041569 spinal fracture Diseases 0.000 description 1
- 208000001413 spine osteoarthritis Diseases 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/063,979 | 2013-10-25 | ||
| US14/063,979 US8802658B2 (en) | 2012-05-14 | 2013-10-25 | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
| US14/279,241 | 2014-05-15 | ||
| US14/279,241 US20140249317A1 (en) | 2012-05-14 | 2014-05-15 | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
| PCT/US2014/050427 WO2015060924A1 (en) | 2013-10-25 | 2014-08-08 | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017121884A Division JP6453387B2 (ja) | 2013-10-25 | 2017-06-22 | 増強した経口バイオアベイラビリティーを有する経口医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016534081A JP2016534081A (ja) | 2016-11-04 |
| JP2016534081A5 JP2016534081A5 (ja) | 2016-12-15 |
| JP6166471B2 true JP6166471B2 (ja) | 2017-07-19 |
Family
ID=52993341
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016526009A Active JP6166471B2 (ja) | 2013-10-25 | 2014-08-08 | ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法 |
| JP2017121884A Active JP6453387B2 (ja) | 2013-10-25 | 2017-06-22 | 増強した経口バイオアベイラビリティーを有する経口医薬組成物 |
| JP2018232467A Active JP6802245B2 (ja) | 2013-10-25 | 2018-12-12 | 増強した経口バイオアベイラビリティーを有する経口医薬組成物 |
| JP2020196080A Active JP7136487B2 (ja) | 2013-10-25 | 2020-11-26 | 増強した経口バイオアベイラビリティーを有する経口医薬組成物 |
| JP2022134019A Pending JP2022162105A (ja) | 2013-10-25 | 2022-08-25 | 増強した経口バイオアベイラビリティーを有する経口医薬組成物 |
| JP2024017350A Pending JP2024040304A (ja) | 2013-10-25 | 2024-02-07 | 増強した経口バイオアベイラビリティーを有する経口医薬組成物 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017121884A Active JP6453387B2 (ja) | 2013-10-25 | 2017-06-22 | 増強した経口バイオアベイラビリティーを有する経口医薬組成物 |
| JP2018232467A Active JP6802245B2 (ja) | 2013-10-25 | 2018-12-12 | 増強した経口バイオアベイラビリティーを有する経口医薬組成物 |
| JP2020196080A Active JP7136487B2 (ja) | 2013-10-25 | 2020-11-26 | 増強した経口バイオアベイラビリティーを有する経口医薬組成物 |
| JP2022134019A Pending JP2022162105A (ja) | 2013-10-25 | 2022-08-25 | 増強した経口バイオアベイラビリティーを有する経口医薬組成物 |
| JP2024017350A Pending JP2024040304A (ja) | 2013-10-25 | 2024-02-07 | 増強した経口バイオアベイラビリティーを有する経口医薬組成物 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3060220A4 (zh) |
| JP (6) | JP6166471B2 (zh) |
| KR (3) | KR101975687B1 (zh) |
| CN (2) | CN108434154A (zh) |
| AU (2) | AU2014340649C1 (zh) |
| CA (1) | CA2928350C (zh) |
| HK (1) | HK1257400A1 (zh) |
| IL (2) | IL245287A0 (zh) |
| MX (1) | MX2016005396A (zh) |
| MY (1) | MY176246A (zh) |
| SG (3) | SG10201609548UA (zh) |
| WO (1) | WO2015060924A1 (zh) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9999629B2 (en) | 2012-05-14 | 2018-06-19 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10413560B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease |
| US9956238B2 (en) | 2014-05-15 | 2018-05-01 | Antecip Bioventures Ii Llc | Compositions for administration of zoledronic acid or related compounds for treating low back pain |
| US10016445B2 (en) | 2012-05-14 | 2018-07-10 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
| US10493085B2 (en) | 2012-05-14 | 2019-12-03 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
| US11654152B2 (en) | 2012-05-14 | 2023-05-23 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
| US10413561B2 (en) | 2012-05-14 | 2019-09-17 | Antecip Bioventures Ii Llc | Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases |
| US10463682B2 (en) | 2012-05-14 | 2019-11-05 | Antecip Bioventures Ii Llc | Compositions for oral administration of zoledronic acid or related compounds for treating low back pain |
| US10350227B2 (en) | 2012-05-14 | 2019-07-16 | Antecip Bioventures Ii Llc | Neridronic acid for treating complex regional pain syndrome |
| CN108434154A (zh) * | 2013-10-25 | 2018-08-24 | 安泰赛普生物风投二代有限责任公司 | 用于治疗疾病的唑来膦酸或相关化合物的经口施用组合物 |
| CN109891021B (zh) | 2016-10-28 | 2022-04-12 | 三菱化学株式会社 | 碳纤维用上浆剂、碳纤维用上浆剂的水分散液、和附着有上浆剂的碳纤维束 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2321864A1 (en) * | 1998-12-25 | 2000-07-06 | Toray Industries, Inc. | Interleukin-6 production inhibitor |
| GB0029111D0 (en) * | 2000-11-29 | 2001-01-10 | Novartis Ag | Organic compounds |
| MXPA03010007A (es) * | 2001-05-02 | 2004-02-12 | Novartis Ag | USO DE BISFOSFONATOS EN EL TRATAMIENTO DE METASTASIS DE HUESO ASOCIADO CON CANCER DE PRoSTATA. |
| US7875597B2 (en) * | 2002-07-24 | 2011-01-25 | New York University | Treatment of spinal mechanical pain |
| AU2003280373A1 (en) * | 2002-10-15 | 2004-05-04 | Novartis Ag | Method of administering bisphosphonates |
| EP1567533B1 (en) * | 2003-07-03 | 2009-03-11 | Teva Pharmaceutical Industries Ltd. | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation |
| AR046773A1 (es) * | 2003-12-23 | 2005-12-21 | Novartis Ag | Formulaciones farmaceuticas de bisfosfonatos |
| HUE034784T2 (en) * | 2009-07-31 | 2018-02-28 | Gruenenthal Gmbh | Crystallization process and bioavailability |
| LT2531200T (lt) * | 2010-02-06 | 2017-09-25 | Grünenthal GmbH | Kristalizacijos būdas ir bioprieinamumas |
| WO2012071517A2 (en) * | 2010-11-24 | 2012-05-31 | Thar Pharmaceuticals, Inc. | Novel crystalline forms |
| AU2013262995B2 (en) * | 2012-05-14 | 2016-09-01 | Antecip Bioventures Ii Llc | Compositions comprising zoledronic acid or related compounds for relieving inflammatory pain and related conditions |
| CN108434154A (zh) * | 2013-10-25 | 2018-08-24 | 安泰赛普生物风投二代有限责任公司 | 用于治疗疾病的唑来膦酸或相关化合物的经口施用组合物 |
-
2014
- 2014-08-08 CN CN201810150156.6A patent/CN108434154A/zh active Pending
- 2014-08-08 KR KR1020177013050A patent/KR101975687B1/ko active IP Right Grant
- 2014-08-08 EP EP14856165.7A patent/EP3060220A4/en not_active Withdrawn
- 2014-08-08 CN CN201480069491.3A patent/CN105960240B/zh active Active
- 2014-08-08 KR KR1020167012645A patent/KR101739244B1/ko active IP Right Grant
- 2014-08-08 AU AU2014340649A patent/AU2014340649C1/en active Active
- 2014-08-08 WO PCT/US2014/050427 patent/WO2015060924A1/en active Application Filing
- 2014-08-08 SG SG10201609548UA patent/SG10201609548UA/en unknown
- 2014-08-08 CA CA2928350A patent/CA2928350C/en active Active
- 2014-08-08 JP JP2016526009A patent/JP6166471B2/ja active Active
- 2014-08-08 SG SG10201800001VA patent/SG10201800001VA/en unknown
- 2014-08-08 SG SG11201603042TA patent/SG11201603042TA/en unknown
- 2014-08-08 MY MYPI2016701480A patent/MY176246A/en unknown
- 2014-08-08 KR KR1020197001788A patent/KR20190009428A/ko not_active Application Discontinuation
- 2014-08-08 MX MX2016005396A patent/MX2016005396A/es unknown
-
2016
- 2016-04-21 IL IL245287A patent/IL245287A0/en unknown
-
2017
- 2017-02-07 AU AU2017200832A patent/AU2017200832A1/en not_active Abandoned
- 2017-06-22 JP JP2017121884A patent/JP6453387B2/ja active Active
- 2017-08-23 IL IL254123A patent/IL254123A0/en unknown
-
2018
- 2018-12-12 JP JP2018232467A patent/JP6802245B2/ja active Active
- 2018-12-26 HK HK18116608.0A patent/HK1257400A1/zh unknown
-
2020
- 2020-11-26 JP JP2020196080A patent/JP7136487B2/ja active Active
-
2022
- 2022-08-25 JP JP2022134019A patent/JP2022162105A/ja active Pending
-
2024
- 2024-02-07 JP JP2024017350A patent/JP2024040304A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6453387B2 (ja) | 増強した経口バイオアベイラビリティーを有する経口医薬組成物 | |
| AU2018214132B2 (en) | Compositions comprising zoledronic acid or related compounds for relieving inflammatory pain and related conditions | |
| US9616078B2 (en) | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease | |
| US9616077B2 (en) | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease | |
| AU2014340649A1 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating disease | |
| WO2016172453A1 (en) | Pharmacodynamic effects after oral administration of zoledronic acid or related compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161012 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161012 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20161012 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20161102 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161122 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170221 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170421 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170530 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170622 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6166471 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |